Sylentis was founded in 2006 as a spin-off within the Zeltia Group, with the mission of building a solid and sustainable business and becoming a therapeutic platform based on RNA interference.

Sylentis’ pipeline is directed towards indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.

Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy has consisted on first selecting accessible therapeutic targets, which don’t require systemic administration of the product. However, the development of formulations which will allow systemic administration without the risk of secondary effects, is an area of great interest to the company.


 Sylentis belongs to         |  Zeltia  Investors   legal info   | RSS     

Sylentis © 2010 •  RNAi Company • All rights reserved | contactlegal info | info@sylentis.com

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.
Utilizamos cookies para mejorar la usabilidad de este sitio web. Las cookies que utilizamos para las operaciones básicas del funcionamiento de esta página ha sido iniciadas. Para saber más sobre el uso de las cookies de este sitio y cómo borrarlas, por favor revise nuestra política de privacidad.
privacy policy / politica de privacidad.

I accept cookies from this site. Acepto las cookies de este sitio.

EU Cookie Directive Module Information